<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056326</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-06333AA1-01</org_study_id>
    <secondary_id>2015-005552-94</secondary_id>
    <nct_id>NCT03056326</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects</brief_title>
  <acronym>CHF6333 FIH</acronym>
  <official_title>A Phase I, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Neutrophil Elastase (HNE) plays a pivotal role in innate immunity and in neutrophilic
      lung inflammation that characterized many diseases. CHF 6333 is a potent and 24h-durable
      inhibitor of HNE, developed as Dry Powder Inhaler (DPI) formulation. This study is designed
      to investigate the tolerability, safety and pharmacokinetics of inhaled CHF6333 DPI in
      healthy male subjects.

      The study will comprise two parts:

      Part 1 will consist of two alternated cohorts of healthy male subjects to assess the safety,
      tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF6333.

      Part 2 will consist of four sequential cohorts of healthy male subjects to assess the safety,
      tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6333
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model_description>Part 1: alternating cross-over design
Part 2: parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1 to 15</time_frame>
    <description>Treatment-related Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital signs</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1 to 15</time_frame>
    <description>Blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15</time_frame>
    <description>Change in Heart Rate (from ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTcF interval</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15</time_frame>
    <description>Change in QTcF interval (from ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PR interval</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15</time_frame>
    <description>Change in PR interval (from ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS interval</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15</time_frame>
    <description>Change in QRS interval (from ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Holter recording abnormalities</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-2 and Day 14-15</time_frame>
    <description>24h-holter ECG recording</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>Part 1 Day 1-2, Part 2 Day 1-14-15</time_frame>
    <description>Change in FEV1 (Forced exhalation volume in the first second)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical chemistry and haematology</measure>
    <time_frame>Part 1 Day 1-5, Part 2 Day 1-15</time_frame>
    <description>change in Clinical chemistry and haematology parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Part 1 Day 1-5, Part 2 Day 1-15</time_frame>
    <description>Change in urinalysis parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
    <description>maximum plasma concentration of CHF6333</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration (tmax)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
    <description>Absolute plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
    <description>plasma volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion (Ae)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
    <description>Amount of CHF6333 excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fraction excreted (fe)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
    <description>Percentage of drug excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>Part 1 from Day 1 to 5, Part 2 from Day 1-2 and Day 14-15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Non-Cystic Fibrosis Bronchiectasis</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CHF6333 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6333 (Part 1 - SAD)</intervention_name>
    <description>Single doses of CHF6333 at each period</description>
    <arm_group_label>CHF6333 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 1 - SAD)</intervention_name>
    <description>Single doses of placebo matching CHF6333 at each period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6333 (Part 2 - MAD)</intervention_name>
    <description>once daily multiple doses of CHF6333 for 14 days</description>
    <arm_group_label>CHF6333 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 2 - MAD)</intervention_name>
    <description>once daily multiple doses of placebo matching CHF6333 for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects aged 18-55 years

          -  BMI between 18-30 kg/m2

          -  Non smokers

          -  Lung function above 80% of predicted normal value

          -  Healthy subjects based on medical evaluation including medical history, physical
             examination, laboratory tests and cardiac testing

        Exclusion Criteria:

          -  Any clinically relevant abnormalities and/or uncontrolled diseases

          -  Abnormal laboratory values

          -  Recent respiratory tract infection

          -  Hypersensitivity to the drug or excipients

          -  Positive serology results

          -  Positive cotinine, alcohol, drug of abuse tests

          -  Unsuitable veins for repeated venepuncture
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Vanhoutte</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Life Sciences</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

